$INSP
Inspire Medical Systems, Inc. Stock $insp

$insp Overview Financials Valuation SEC Filings Company Website

2020 Q1 Form 10-Q Financial Statement

#000160955020000024 Filed on May 05, 2020

Income Statement

Concept	2020 Q1	2019 Q1
Revenue	$21.35M	$16.25M
YoY Change	31.37%	61.82%
Cost Of Revenue	$3.297M	$2.854M
YoY Change	15.52%	24.41%
Gross Profit	$18.05M	$13.40M
YoY Change	34.74%	72.9%
Gross Profit Margin	84.56%	82.44%
Selling, General & Admin	$29.05M	$19.57M
YoY Change	48.44%	74.58%
% of Gross Profit	160.94%	146.09%
Research & Development	$5.438M	$2.603M
YoY Change	108.91%	50.46%
% of Gross Profit	30.13%	19.43%
Depreciation & Amortization	$187.0K	$103.0K
YoY Change	81.55%	14.44%
% of Gross Profit	1.04%	0.77%
Operating Expenses	$34.49M	$22.17M
YoY Change	55.55%	71.31%
Operating Profit	-$16.44M	-$8.777M
YoY Change	87.31%	68.95%
Interest Expense	$525.0K	$537.0K
YoY Change	-2.23%	-61.23%
% of Operating Profit
Other Income/Expense, Net	$195.0K	$511.0K
YoY Change	-61.84%	-139.13%
Pretax Income	-$16.25M	-$8.266M
YoY Change	96.53%	27.15%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$16.25M	-$8.266M
YoY Change	96.53%	27.15%
Net Earnings / Revenue	-76.1%	-50.87%
Basic Earnings Per Share
Diluted Earnings Per Share	-$672.3K	-$352.8K
COMMON SHARES
Basic Shares Outstanding	24.13M shares	23.44M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2020 Q1	2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$135.7M	$177.0M
YoY Change	-23.33%	888.83%
Cash & Equivalents	$76.12M	$101.9M
Short-Term Investments	$59.60M	$75.10M
Other Short-Term Assets	$1.400M	$1.400M
YoY Change	0.0%	-36.36%
Inventory	$7.245M	$3.106M
Prepaid Expenses	$1.429M	$1.726M
Receivables	$11.03M	$7.036M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$155.4M	$199.3M
YoY Change	-22.0%	640.78%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.113M	$974.0K
YoY Change	219.61%	8.22%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$6.100M
YoY Change
Other Assets	$400.0K	$100.0K
YoY Change	300.0%
Total Long-Term Assets	$10.31M	$824.0K
YoY Change	1150.61%	-17.6%
TOTAL ASSETS
Total Short-Term Assets	$155.4M	$199.3M
Total Long-Term Assets	$10.31M	$824.0K
Total Assets	$165.7M	$200.1M
YoY Change	-17.17%	617.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.800M	$3.200M
YoY Change	81.25%	-17.95%
Accrued Expenses	$7.896M	$7.740M
YoY Change	2.02%	134.55%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$13.72M	$11.17M
YoY Change	22.81%	41.38%
LONG-TERM LIABILITIES
Long-Term Debt	$24.60M	$24.40M
YoY Change	0.82%	2.09%
Other Long-Term Liabilities	$40.00K
YoY Change
Total Long-Term Liabilities	$40.00K	$24.40M
YoY Change	-99.84%	-2.01%
TOTAL LIABILITIES
Total Short-Term Liabilities	$13.72M	$11.17M
Total Long-Term Liabilities	$40.00K	$24.40M
Total Liabilities	$38.33M	$36.10M
YoY Change	6.2%	10.05%
SHAREHOLDERS EQUITY
Retained Earnings	-$196.4M	-$155.2M
YoY Change	26.56%
Common Stock	$24.00K	$24.00K
YoY Change	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$127.4M	$157.4M
YoY Change
Total Liabilities & Shareholders Equity	$165.7M	$200.1M
YoY Change	-17.17%	617.18%

Cashflow Statement

Concept	2020 Q1	2019 Q1
OPERATING ACTIVITIES
Net Income	-$16.25M	-$8.266M
YoY Change	96.53%	27.15%
Depreciation, Depletion And Amortization	$187.0K	$103.0K
YoY Change	81.55%	14.44%
Cash From Operating Activities	-$14.78M	-$10.94M
YoY Change	35.03%	70.49%
INVESTING ACTIVITIES
Capital Expenditures	$255.0K	$275.0K
YoY Change	-7.27%	3828.57%
Acquisitions
YoY Change
Other Investing Activities	$67.50M	$16.23M
YoY Change	315.9%	3674.42%
Cash From Investing Activities	$67.24M	$15.96M
YoY Change	321.42%	3654.35%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$787.0K	-$366.0K
YoY Change	-315.03%	-104.47%
NET CHANGE
Cash From Operating Activities	-$14.78M	-$10.94M
Cash From Investing Activities	$67.24M	$15.96M
Cash From Financing Activities	$787.0K	-$366.0K
Net Change In Cash	$53.26M	$4.657M
YoY Change	1043.59%	112.45%
FREE CASH FLOW
Cash From Operating Activities	-$14.78M	-$10.94M
Capital Expenditures	$255.0K	$275.0K
Free Cash Flow	-$15.03M	-$11.22M
YoY Change	33.99%	74.58%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2020Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2020Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001609550
CY2020Q1	dei	Amendment Flag AmendmentFlag	false
CY2020Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2020Q1	insp	Accounts Receivable Allowance For Credit Loss Current AccountsReceivableAllowanceForCreditLossCurrent	35000	USD
CY2020Q1	dei	Document Type DocumentType	10-Q
CY2020Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2020Q1	dei	Document Period End Date DocumentPeriodEndDate	2020-03-31
CY2020Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2020Q1	dei	Entity File Number EntityFileNumber	001-38468
CY2020Q1	dei	Entity Registrant Name EntityRegistrantName	Inspire Medical Systems, Inc.
CY2020Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2020Q1	dei	Entity Shell Company EntityShellCompany	false
CY2020Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-1377674
CY2020Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	5500 Wayzata Blvd.
CY2020Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 1600
CY2020Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Golden Valley
CY2020Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	MN
CY2020Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	55416
CY2020Q1	dei	City Area Code CityAreaCode	844
CY2020Q1	dei	Local Phone Number LocalPhoneNumber	672-4357
CY2020Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value per share
CY2020Q1	dei	Trading Symbol TradingSymbol	INSP
CY2020Q1	dei	Security Exchange Name SecurityExchangeName	NYSE
CY2020Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2020Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2020Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	26676720	shares
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	76117000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22860000	USD
CY2020Q1	us-gaap	Short Term Investments ShortTermInvestments	59608000	USD
CY2019Q4	us-gaap	Short Term Investments ShortTermInvestments	126605000	USD
CY2020Q1	insp	Accounts Receivable Allowance For Credit Loss Current AccountsReceivableAllowanceForCreditLossCurrent	35000	USD
CY2019Q4	insp	Accounts Receivable Allowance For Credit Loss Current AccountsReceivableAllowanceForCreditLossCurrent	48000	USD
CY2020Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	11032000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	13131000	USD
CY2020Q1	us-gaap	Inventory Net InventoryNet	7245000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	5834000	USD
CY2020Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1429000	USD
CY2019Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2206000	USD
CY2020Q1	us-gaap	Assets Current AssetsCurrent	155431000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	170636000	USD
CY2020Q1	us-gaap	Long Term Investments LongTermInvestments	6139000	USD
CY2019Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	4459000	USD
CY2019Q4	us-gaap	Long Term Investments LongTermInvestments	6276000	USD
CY2020Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3113000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3045000	USD
CY2020Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	672000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	915000	USD
CY2020Q1	us-gaap	Investments And Other Noncurrent Assets InvestmentsAndOtherNoncurrentAssets	381000	USD
CY2019Q4	us-gaap	Investments And Other Noncurrent Assets InvestmentsAndOtherNoncurrentAssets	381000	USD
CY2020Q1	us-gaap	Assets Assets	165736000	USD
CY2019Q4	us-gaap	Assets Assets	181253000	USD
CY2020Q1	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	5821000	USD
CY2020Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7896000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12397000	USD
CY2020Q1	us-gaap	Liabilities Current LiabilitiesCurrent	13717000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	16856000	USD
CY2020Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	24576000	USD
CY2019Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	24522000	USD
CY2020Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	40000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	40000	USD
CY2020Q1	us-gaap	Liabilities Liabilities	38333000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	41418000	USD
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2020Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2020Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	24362389	shares
CY2020Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	24362389	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	24107350	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	24107350	shares
CY2020Q1	us-gaap	Common Stock Value CommonStockValue	24000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	24000	USD
CY2020Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	323473000	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	319865000	USD
CY2020Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	295000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	102000	USD
CY2020Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-196389000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-180156000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	127403000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	139835000	USD
CY2020Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	165736000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	181253000	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	21347000	USD
CY2019Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	16250000	USD
CY2020Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3297000	USD
CY2019Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2854000	USD
CY2020Q1	us-gaap	Gross Profit GrossProfit	18050000	USD
CY2019Q1	us-gaap	Gross Profit GrossProfit	13396000	USD
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5438000	USD
CY2019Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2603000	USD
CY2020Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	29052000	USD
CY2019Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	19570000	USD
CY2020Q1	us-gaap	Operating Expenses OperatingExpenses	34490000	USD
CY2019Q1	us-gaap	Operating Expenses OperatingExpenses	22173000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-16440000	USD
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-8777000	USD
CY2020Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	642000	USD
CY2019Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	1086000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-8266000	USD
CY2020Q1	us-gaap	Interest Expense InterestExpense	525000	USD
CY2019Q1	us-gaap	Interest Expense InterestExpense	537000	USD
CY2020Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	78000	USD
CY2019Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-38000	USD
CY2020Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	195000	USD
CY2019Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	511000	USD
CY2020Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-16245000	USD
CY2019Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8266000	USD
CY2020Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2019Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020Q1	us-gaap	Profit Loss ProfitLoss	-16245000	USD
CY2019Q1	us-gaap	Profit Loss ProfitLoss	-8266000	USD
CY2020Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	193000	USD
CY2019Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	68000	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16052000	USD
CY2019Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8198000	USD
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.67
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.35
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	24165875	shares
CY2019Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	23441560	shares
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	139835000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	787000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	72000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	2749000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	193000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-16245000	USD
CY2020Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	127403000	USD
CY2018Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	163999000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	166000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	58000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1391000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	68000	USD
CY2019Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	157416000	USD
CY2020Q1	us-gaap	Profit Loss ProfitLoss	-16245000	USD
CY2019Q1	us-gaap	Profit Loss ProfitLoss	-8266000	USD
CY2020Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	187000	USD
CY2019Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	103000	USD
CY2020Q1	us-gaap	Investment Income Amortization Of Discount InvestmentIncomeAmortizationOfDiscount	80000	USD
CY2019Q1	us-gaap	Investment Income Amortization Of Discount InvestmentIncomeAmortizationOfDiscount	309000	USD
CY2020Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	54000	USD
CY2019Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	110000	USD
CY2020Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	243000	USD
CY2019Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	204000	USD
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2749000	USD
CY2019Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1391000	USD
CY2020Q1	insp	Sharebased Compensation Noncash Services SharebasedCompensationNoncashServices	72000	USD
CY2019Q1	insp	Sharebased Compensation Noncash Services SharebasedCompensationNoncashServices	58000	USD
CY2020Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	89000	USD
CY2019Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	141000	USD
CY2020Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-2092000	USD
CY2019Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	385000	USD
CY2020Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1411000	USD
CY2019Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	439000	USD
CY2020Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-775000	USD
CY2019Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-212000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1372000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-222000	USD
CY2020Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-4494000	USD
CY2019Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-3258000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14775000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10942000	USD
CY2020Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	255000	USD
CY2019Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	275000	USD
CY2020Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	14907000	USD
CY2019Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	40573000	USD
CY2020Q1	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	82403000	USD
CY2019Q1	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	56804000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	67241000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	15956000	USD
CY2020Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2019Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	531000	USD
CY2020Q1	insp	Proceeds From Stock Options And Warrants Exercised ProceedsFromStockOptionsAndWarrantsExercised	787000	USD
CY2019Q1	insp	Proceeds From Stock Options And Warrants Exercised ProceedsFromStockOptionsAndWarrantsExercised	165000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	787000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-366000	USD
CY2020Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4000	USD
CY2019Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	53257000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	4657000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	22860000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	97288000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	76117000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	101945000	USD
CY2020Q1	us-gaap	Interest Paid Net InterestPaidNet	471000	USD
CY2019Q1	us-gaap	Interest Paid Net InterestPaidNet	771000	USD
CY2020Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements. We use significant judgment when making estimates related to the allowance for credit losses, inventory reserves, warranty reserves, and the valuation of stock-based awards. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.</span></div>
CY2020Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	300000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	100000	USD
CY2020Q1	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	100000	USD
CY2019Q1	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	0	USD
CY2020Q1	us-gaap	Fair Value Liabilities Level1 To Level2 Transfers Amount FairValueLiabilitiesLevel1ToLevel2TransfersAmount	0	USD
CY2019Q4	us-gaap	Fair Value Liabilities Level1 To Level2 Transfers Amount FairValueLiabilitiesLevel1ToLevel2TransfersAmount	0	USD
CY2019Q4	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0	USD
CY2019Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2020Q1	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0	USD
CY2020Q1	us-gaap	Fair Value Liabilities Level2 To Level1 Transfers Amount FairValueLiabilitiesLevel2ToLevel1TransfersAmount	0	USD
CY2020Q1	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2019Q4	us-gaap	Fair Value Liabilities Level2 To Level1 Transfers Amount FairValueLiabilitiesLevel2ToLevel1TransfersAmount	0	USD
CY2020Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Concentration of Credit Risk</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Financial instruments, which potentially subject us to concentrations of credit risk, consist principally of cash equivalents, investments, and accounts receivable. </span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our investment policy limits investments to certain types of debt securities issued by the U.S. government and its agencies, corporations with investment-grade credit ratings, or commercial paper and money market funds issued by the highest quality financial and non-financial companies. We place restrictions on maturities and concentration by type and issuer. We are exposed to credit risk in the event of a default by the issuers of these securities to the extent recorded on the balance sheets. However, as of March 31, 2020 and December 31, 2019, we limited our credit risk associated with cash equivalents by placing investments with banks we believe are highly creditworthy.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We believe that the credit risk in our accounts receivable is mitigated by our credit evaluation process, relatively short collection terms, and dispersion of our customer base. We generally do not require collateral, and losses on accounts receivable have historically been within management's expectations.</span></div>
CY2020Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	961000	USD
CY2019Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	781000	USD
CY2020Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	6284000	USD
CY2019Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	5053000	USD
CY2020Q1	us-gaap	Inventory Net InventoryNet	7245000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	5834000	USD
CY2019Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	100000	USD
CY2020Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	100000	USD
CY2020Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4305000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4050000	USD
CY2020Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1192000	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1005000	USD
CY2020Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3113000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3045000	USD
CY2020Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	200000	USD
CY2019Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	100000	USD
CY2020Q1	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	6299000	USD
CY2019Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	10304000	USD
CY2020Q1	us-gaap	Interest Payable Current InterestPayableCurrent	160000	USD
CY2019Q4	us-gaap	Interest Payable Current InterestPayableCurrent	160000	USD
CY2020Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	585000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	828000	USD
CY2020Q1	us-gaap	Advertising Expense AdvertisingExpense	6400000	USD
CY2019Q1	us-gaap	Advertising Expense AdvertisingExpense	3500000	USD
CY2020Q1	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	0	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	0	USD
CY2020Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	852000	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1105000	USD
CY2020Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7896000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12397000	USD
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2020Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2019Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	1800000	USD
CY2019Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1800000	USD
CY2020Q1	insp	Operating Leases Future Minimum Payments Net Present Value OperatingLeasesFutureMinimumPaymentsNetPresentValue	7400000	USD
CY2020Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	672000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	915000	USD
CY2020Q1	insp	Operating Lease Liability Gross OperatingLeaseLiabilityGross	585000	USD
CY2019Q4	insp	Operating Lease Liability Gross OperatingLeaseLiabilityGross	828000	USD
CY2020Q1	insp	Operating Lease Remaining Lease Term OperatingLeaseRemainingLeaseTerm	P0Y8M12D
CY2020Q1	insp	Operating Lease Remaining Lease Discount Rate Percent OperatingLeaseRemainingLeaseDiscountRatePercent	0.080
CY2020Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	300000	USD
CY2019Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	200000	USD
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	66974	shares
CY2020Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	0	USD
CY2020Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	0	USD
CY2020Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	9188000	USD
CY2020Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	12250000	USD
CY2020Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	3062000	USD
CY2020Q1	us-gaap	Long Term Debt LongTermDebt	24500000	USD
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2844164	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	30.41
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y10M24D
CY2019Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	124585000	USD
CY2020Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2749000	USD
CY2019Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1391000	USD
CY2020Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	33000000.0	USD
CY2020Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y10M24D
CY2020Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	100000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	100000	USD
CY2020Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	21347000	USD
CY2019Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	16250000	USD
CY2020Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2625789	shares
CY2019Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2702108	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	71.13
CY2020Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	254142	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.10
CY2020Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested	13782000	USD
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	31207	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	29.47
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2625789	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	34.10
CY2020Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y10M24D
CY2020Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	76037000	USD
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1068835	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	11.63
CY2020Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y4M24D
CY2020Q1	insp	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Exercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable	52002000	USD

Files In Submission

Name	View Source	Status
0001609550-20-000024-index-headers.html	Edgar Link	pending
0001609550-20-000024-index.html	Edgar Link	pending
0001609550-20-000024.txt	Edgar Link	pending
0001609550-20-000024-xbrl.zip	Edgar Link	pending
a2020-q1ex31x1.htm	Edgar Link	pending
a2020-q1ex31x2.htm	Edgar Link	pending
a2020-q1ex32x1.htm	Edgar Link	pending
a2020-q1ex32x2.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
insp-20200331.htm	Edgar Link	pending
insp-20200331.xsd	Edgar Link	pending
insp-20200331_cal.xml	Edgar Link	unprocessable
insp-20200331_def.xml	Edgar Link	unprocessable
insp-20200331_g1.jpg	Edgar Link	pending
insp-20200331_htm.xml	Edgar Link	completed
insp-20200331_lab.xml	Edgar Link	unprocessable
insp-20200331_pre.xml	Edgar Link	unprocessable
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$INSP
Inspire Medical Systems, Inc. Stock $insp

2020 Q1 Form 10-Q Financial Statement

#000160955020000024 Filed on May 05, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INSP Inspire Medical Systems, Inc. Stock $insp

2020 Q1 Form 10-Q Financial Statement

#000160955020000024 Filed on May 05, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INSP
Inspire Medical Systems, Inc. Stock $insp